Ariella P. Golomb, MD

Managing Director

Dr. Golomb brings expertise in medicine and strategy to HealthpointCapital. She is a member of the Firm’s investment team, manages the Firm’s Scientific Advisory Board and other clinical relationships and oversees the operations of the Firm. Prior to joining HealthpointCapital, Dr. Golomb was a Project Leader for the Health Care Practice of the Boston Consulting Group, where she advised global life science companies on strategic management issues including product positioning, sales force restructuring and academic medical center alliances. While in business school, Dr. Golomb worked at Wyeth Pharmaceuticals in the Women’s Health Marketing division. She is a member of the Board of Directors of OrthoSpace Ltd. and the Executive Council of the Department of Health Policy and Management at the Harvard School of Public Health. Dr. Golomb received a B.A. and graduated Phi Beta Kappa from the University of Pennsylvania’s College of Arts and Sciences. She went on to receive an M.B.A. from the Wharton School with a concentration in Health Care Management and an M.D. from the School of Medicine.


Recent Articles by Ariella P. Golomb, MD

Baxter to Acquire ApaTech for up to $330 million MAR 1, 2010

apatech%20logo_small.JPGBaxter announced plans to acquire ApaTech for up to $330 million, with $240 million in cash up front (a 4x revenue multiple) and additional milestone payments of up to $90 million. more

Osiris' New Biosurgery Division to Focus on Bone Repair AUG 5, 2009

Osiris Therapeutics has been at the forefront of developing stem-cell-based products in orthopedics, most notably with their commercialization of Osteocel. That product line was sold to NuVasive last year, leaving Orthofix (who had previously distributed Osteocel under the name Trinity)... more

A Look at the Medical Device Industry Today JUN 3, 2009

Venture capital companies believe the dynamics and fundamentals and the medical technology industry haven't changed, even though the economic crisis is causing a revaluing of assets. Many VC-backed companies are expecting down rounds, particularly as midstage assets are revalued. These... more

Stryker's OP-1 Putty Not Approvable According to FDA Panel APR 1, 2009

Yesterday an FDA advisory panel voted 6-1 that Stryker's PMA for its OP-1 Putty for uninstrumented posterolateral fusion for the treatment of lumbar spondylolisthesis was "not approvable." Stryker was seeking this approval based on 24 months of clinical outcome data... more

Musculoskeletal News Roundup 6-Dec-07 DEC 7, 2007

As originally announced back in June, this week the Supreme Court heard a Medtronic case involving a failed balloon catheter. The decision of the case could have broader implications for the FDA's authority and product liability. According to the... more